NASDAQ · Health care

Acurx Pharmaceuticals, Inc. (ACXP)

It posted a net loss of $7.5M. At June 30, 2026 it held $10.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Price

$1.36

0.00% on the day · September 25, 2026

52-week range $1.31 to $8.34

Market cap

$7.2M

What Acurx Pharmaceuticals, Inc. does

Acurx Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACXP.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$8.1M	-$8M	-$5.32	n/a
2024	n/a	-$14.1M	-$14.1M	-$17.45	n/a
2023	n/a	n/a	-$14.6M	-$23.07	n/a
2022	n/a	n/a	-$12.1M	-$22.46	n/a
2021	n/a	n/a	-$12.7M	-$29.89	n/a
2021	n/a	n/a	-$4.6M	-$14.84	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 11, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 12, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Acurx Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 17, 2026
Securities offering prospectus 424B3
September 8, 2026
IPO registration S-1
September 1, 2026
Annual report to shareholders ARS
September 1, 2026
Additional proxy material DEFA14A
September 1, 2026
Proxy statement DEF 14A
August 13, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.53 versus -$1.89.
May 12, 2026
Securities offering prospectus 424B3
May 12, 2026
Securities offering prospectus 424B3
May 11, 2026
Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.62 versus -$2.15.
May 4, 2026
IPO registration S-1

Recent insider filings (Forms 3, 4 and 144): 10, the latest on April 22, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about ACXP

What does Acurx Pharmaceuticals, Inc. do?

Acurx Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACXP.

Is Acurx Pharmaceuticals, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $7.5M.

When did Acurx Pharmaceuticals, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the securities offering prospectus from September 17, 2026.

Similar companies

Compare ACXP with

Compare ACXP with any company

Follow ACXP

Get an email when Acurx Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ACXP: get an email when it files

Where the numbers come from

Financial figures are the values Acurx Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.